Thomas H. McLain Appointed to the Biotechnology Industry
Organization's Board of Directors

Nabi Biopharmaceuticals (Nasdaq: NABI - News) announced today that
its chairman, chief executive officer and president, Thomas H.
McLain, has been appointed to the Board of Directors of the
Biotechnology Industry Organization (BIO), effective June 21, 2005.
Mr. McLain is one of eleven new Board members, who will each serve
two-year terms.

BIO represents more than 1,000 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
in all 50 U.S. states and 33 other nations. BIO members are involved
in the research and development of healthcare, agricultural,
industrial and environmental biotechnology products.

"Biotechnology's impact on human health has never been greater; its
discoveries are beginning to realize their great promise. I am
honored to accept this Board position, as our industry continues to
serve as a leading force in the advancement of 21st century
medicine," said Mr. McLain.

Mr. McLain joined Nabi Biopharmaceuticals in 1998 and today serves
as chairman, chief executive officer and president of the company.
From 1988 to 1998, Mr. McLain was employed by Bausch & Lomb,
Incorporated. He earned his B.A. in Economics at College of the Holy
Cross and an M.B.A. from the William E. Simon Graduate School of
Business at the University of Rochester. He is a member of the Board
of Directors of Eastman Chemical Company and serves as the Chairman
of BioFlorida.

"Tom McLain is a widely recognized leader in the emerging life
sciences arena both nationally and internationally," said Florida
Governor Jeb Bush. "As Florida is increasingly positioned at the
epicenter of this industry, we are fortunate to have someone of
Tom's caliber contributing on a national scale. I applaud BIO's
decision to recognize Tom's commitment to and noted achievements in
biotechnology, and look forward to his ongoing leadership to escort
the industry to new heights."

"Tom McLain's knowledge, experience and vision make him an ideal
addition to our Board of Directors," said BIO President James
Greenwood. "In particular, we value his expertise in vaccines and
his role in the emergence of biotech in Florida."

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. We are poised to capture large,
commercial opportunities in our four core business areas: Gram-
positive bacterial infections, hepatitis, kidney disease
(nephrology), and nicotine addiction. We have three products on the
market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B
Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for
injection)] and a number of products in various stages of clinical
and preclinical development. The company filed its Marketing
Authorization Application in Europe for its product candidate,
StaphVAX® [Staphylococcus aureus Polysaccharide Conjugate Vaccine],
in December 2004. The application was accepted for review in January
2005. StaphVAX is currently in a confirmatory Phase III clinical
trial in the U.S. StaphVAX is designed to prevent the most dangerous
and prevalent strains of Staphylococcus aureus bacterial infections.
S. aureus bacteria are a major cause of hospital-acquired infections
and are becoming increasingly resistant to antibiotics. The
company's other products in development include Altastaph(TM)
[Staphylococcus aureus Immune Globulin Intravenous (Human)], an
antibody for prevention and treatment of S. aureus infections, NicVAX
(TM) [Nicotine Conjugate Vaccine], a vaccine to treat nicotine
addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an
antibody for preventing hepatitis C virus re-infection in liver
transplant patients. For additional information on Nabi
Biopharmaceuticals, please visit our website at:
http://www.nabi.com .

This press release contains forward-looking statements that reflect
the company's current expectations regarding future events. Any such
forward- looking statements are not guarantees of future performance
and involve significant risks and uncertainties. Actual results may
differ significantly from those in the forward-looking statements as
a result of any number of factors, including, but not limited to,
risks relating to the possibility that our confirmatory Phase III
clinical trial for StaphVAX or our plans to commercialize StaphVAX
in the European Union and United States may not be successful; the
possibility that we may not realize the value of our acquisition of
PhosLo; the company's ability to raise additional capital on
acceptable terms; the company's dependence upon third parties to
manufacture its products; the company's ability to utilize the full
capacity of its manufacturing facility; the impact on sales of Nabi-
HB from patient treatment protocols and the number of liver
transplants performed in HBV-positive patients; reliance on a small
number of customers; the future sales growth prospects for the
company's biopharmaceutical products; and the company's ability to
obtain regulatory approval for its products in the United States or
abroad or to successfully develop, manufacture and market its
products. These factors are more fully discussed in the company's
Annual Report on Form 10-K for the fiscal year ended December 25,
2004 filed with the Securities and Exchange Commission.

---------------------------------------------------------------------
-----------
Source: Nabi Biopharmaceuticals

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech